Shares of Oculis Holding AG (NASDAQ:OCS - Get Free Report) gapped up before the market opened on Wednesday . The stock had previously closed at $17.99, but opened at $19.00. Oculis shares last traded at $18.92, with a volume of 21,365 shares traded.
Wall Street Analysts Forecast Growth
A number of brokerages have recently issued reports on OCS. HC Wainwright reissued a "buy" rating and issued a $30.00 target price on shares of Oculis in a research report on Monday, January 6th. Chardan Capital reissued a "buy" rating and issued a $28.00 target price on shares of Oculis in a research report on Tuesday, January 7th.
Get Our Latest Research Report on Oculis
Oculis Stock Performance
The firm has a market cap of $763.10 million, a price-to-earnings ratio of -9.76 and a beta of 0.01. The stock has a 50 day moving average of $20.77 and a 200 day moving average of $16.77. The company has a quick ratio of 4.02, a current ratio of 4.02 and a debt-to-equity ratio of 0.01.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Citadel Advisors LLC acquired a new position in Oculis in the fourth quarter valued at about $389,000. Bank of America Corp DE raised its stake in Oculis by 58.2% in the fourth quarter. Bank of America Corp DE now owns 28,980 shares of the company's stock valued at $493,000 after purchasing an additional 10,667 shares in the last quarter. Bellevue Group AG acquired a new position in Oculis in the fourth quarter valued at about $170,000. XTX Topco Ltd acquired a new position in Oculis during the fourth quarter worth about $225,000. Finally, Geode Capital Management LLC raised its stake in Oculis by 12.0% during the fourth quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock worth $284,000 after acquiring an additional 1,800 shares in the last quarter. Institutional investors and hedge funds own 22.30% of the company's stock.
Oculis Company Profile
(
Get Free Report)
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Featured Stories
Before you consider Oculis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oculis wasn't on the list.
While Oculis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
